Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review

Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review

Abstract Oncogene-addicted non-small cell lung cancer (NSCLC) comprises a number of distinct disease subtypes, each of which is characterised by druggable genetic alterations. Among them, the receptor tyrosine kinase protein human epidermal receptor 2 (HER2) is occasionally found deregulated via gen...

Full description

Bibliographic Details
Main Authors: Giulio Metro, Sara Baglivo, Riccardo Moretti, Guido Bellezza, Angelo Sidoni, Fausto Roila
Format: Article
Language:English
Published: Adis, Springer Healthcare 2020-07-01
Series:Oncology and Therapy
Subjects:
Beyond progression
HER2 mutation
Non-small cell lung cancer
Poziotinib
Trastuzumab
Online Access:https://doi.org/10.1007/s40487-020-00121-5

Internet

https://doi.org/10.1007/s40487-020-00121-5

Similar Items